Who we are

ENSEM Therapeutics (“ENSEM”) is a Boston-based, preclinical stage biopharmaceutical company focused on high value and difficult-to-drug targets in oncology to address unmet medical needs. The name ENSEM symbolizes innovations via the integration of groundbreaking technologies to decipher structural ENSEMbles and kinetics for drug design. The company’s mission is to discover, develop, and commercialize transformative oncology therapies for patients, while leading the advancement of AI-driven structural ensemble and computational drug design.

ENSEM is incubated by CBC Group, one of the largest healthcare investment funds with $5B+ AUM (Asset Under Management) (http://www.cbridgecap.com).

Protein dynamic ensemble: A small molecule (in orange) binds and induces the opening of a cryptic pocket and distal protein conformational change (blue), while the cofactor (green) stays associated.

Our Leaders

ENSEM has assembled an experienced leadership team with proven track records across continuum of R&D disciplines from computer-aided drug design enhanced by AI-based technology, biophysics & structure biology, chemistry, DMPK, to biochemistry and biology. This extensive and complementary experience is essential to drive our scientific vision and accelerate innovative therapeutics to patients in need.

Sean Cao, Ph.D., MBA
Board Director, Chief Executive Officer

Shenfang Jin, Ph.D.
Board Director, President, CSO

Tai Wong, Ph.D.
Senior VP, Head of Biology

Tao Liu, Ph.D.
VP,  Head of Chemistry

Raj Nagaraja, Ph.D.
VP,  Head of DMPK

Ming-Hong Hao, Ph.D.
VP,  Head of Computational Chemistry

Katya Henderson, Ph.D.
VP,  Operations

Joanna Wu
General Counsel

Michael Haley
VP, Human Resources

Ivet Bahar, Ph.D.
Scientific Advisor

Carlos Garcia Echeverria, Ph.D.
Scientific Advisor

Brian Kuhlman, Ph.D.
Scientific Advisor

Cheng Luo, Ph.D.
Co-Founder and Scientific Advisor

Zhihua Sui, Ph.D.
Scientific Advisor

Mengdi Wang, Ph.D.
Scientific Advisor

Qi Zhang, Ph.D.
Co-Founder and Scientific Advisor